The positive outcome of the Phase 2/3 CALINA study for Novartis's formulated Coartem for babies under 5kg with malaria suggests a successful development and potential market entry of a new product. This could lead to increased revenues for Novartis in the pharmaceutical sector, especially in markets with high malaria prevalence. The announcement directly impacts Novartis's stock as it highlights the company's R&D capabilities and potential for future growth in the healthcare sector.